Development and validation of a nomogram model for the prediction of 4L lymph node metastasis in thoracic esophageal squamous cell carcinoma

Lei Xu1, Jia Guo2, Shu Qi1, Hou-nai Xie1, Xiu-feng Wei1, Yong-kui Yu3, Ping Cao4, Rui-xiang Zhang1, Xian-kai Chen1* and Yin Li1*

1Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 2Department of Radiology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China, 3Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China, 4Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China

Objectives: The left tracheobronchial (4L) lymph nodes (LNs) are considered as regional LNs for esophageal squamous cell carcinoma (ESCC), but there is a controversy about routine prophylactic 4L LN dissection for all resectable ESCCs. This study aimed to develop a nomogram for preoperative prediction of station 4L lymph node metastases (LNMs).

Methods: A total of 522 EC patients in the training cohort and 370 in the external validation cohort were included. The prognostic impact of station 4L LNM was evaluated, and multivariable logistic regression analyses were performed to identify independent risk factors of station 4L LNM. A nomogram model was developed based on multivariable logistic regression analysis. Model performance was evaluated in both cohorts in terms of calibration, discrimination, and clinical usefulness.

Results: The incidence of station 4L LNM was 7.9% (41/522) in the training cohort. Patients with station 4L LNM exhibited a poorer 5-year overall survival rate than those without (43.2% vs. 71.6%, p < 0.001). In multivariate logistic regression analyses, six variables were confirmed as independent 4L LNM risk factors: sex (p = 0.039), depth of invasion (p = 0.002), tumor differentiation (p = 0.016), short axis of the largest 4L LNs (p = 0.001), 4L conglomeration (p = 0.006), and 4L necrosis (p = 0.002). A nomogram model, containing six independent risk factors, demonstrated a good performance, with the area under the curve (AUC) of 0.921 (95% CI: 0.878–0.954) in the training cohort and 0.892 (95% CI: 0.830–0.954) in the validation cohort. The calibration curve...
showed a good agreement on the presence of station 4L LNM between the risk estimation according to the model and histopathologic results on surgical specimens. The Hosmer–Lemeshow test demonstrated a non-significant statistic (p = 0.691 and 0.897) in the training and validation cohorts, which indicated no departure from the perfect fit. Decision curve analysis indicated that the model had better diagnostic power for 4L LNM than the traditional LN size criteria.

**Conclusions:** This model integrated the available clinical and radiological risk factors, facilitating in the precise prediction of 4L LNM in patients with ESCC and aiding in personalized therapeutic decision-making regarding the need for routine prophylactic 4L lymphadenectomy.

**KEYWORDS**
left tracheobronchial (4L) lymph nodes, lymphadenectomy, nomogram, lymph node metastases, esophageal squamous cell carcinoma

**Introduction**

Esophageal cancer (EC) ranks seventh in terms of cancer incidence and sixth in cancer-related mortality overall (1). Esophageal squamous cell carcinoma (ESCC) is one of the two major histological types of EC. Despite advances in screening and treatment, ESCC remains a highly lethal disease. The presence of lymph node metastases (LNMs) is one of the most important factors associated with poor prognosis (2, 3). Currently, radical esophagectomy combined with lymphadenectomy is the main treatment strategy for resectable ESCC (4). The left tracheobronchial lymph nodes (4L) are considered regional lymph nodes (LNs) for EC, but the 4L lymph node was not routinely dissected for all patients with resectable EC due to the high operative risk (5–7). The 4L lymph nodes are located deeply within the subaortic region close to the left recurrent laryngeal nerve, aortic arch, left pulmonary artery, and left main bronchial membrane, making the possibility of dissection-related damages increased and the procedure more technically challenging and time-consuming (7, 8). Therefore, a robust preoperative assessment of 4L lymph nodes is of great necessity.

Preoperative prediction of lymph node status is critical to determine the scope and method of individualized lymph node dissection for patients (9–11). Unfortunately, the current radiological assessment fails to provide reliable nodal metastasis information tailored to the individual patient. LNM is mainly assessed by imaging characteristics, including computed tomography (CT) and positron emission tomography (PET)/CT. PET/CT can significantly improve the detection of distant metastasis but shows well-known drawbacks of moderate specificity and sensitivity for the detection of locoregional node metastasis (9, 10). Moreover, many centers did not routinely perform PET/CT as the initial workup, especially in areas with poor economy or equipment. Diagnostic imaging techniques using size on CT images (>1.0 cm in short-axis diameter) as the criterion of LNM cannot exactly assess the intrathoracic nodal status in EC (11, 12). Therefore, the current radiological practice may not be adequate for the appropriate 4L LNM risk stratiﬁcation of patients, and robust predictive models for preoperative assessment of nodal metastasis are of great necessity. This study aimed to develop and validate a nomogram that incorporates clinical and radiological risk factors to predict 4L LNM in ESCC and facilitate the optimal management of 4L LNs.

**Patients and methods**

**Study population**

A total of 892 patients who underwent radical esophagectomy and 4L lymphadenectomy were included, according to the following inclusion criteria: (1) pathological diagnosis of thoracic ESCC, (2) patients who received radical esophagectomy and 4L lymphadenectomy, (3) patients who did not receive neoadjuvant therapy, and 4) patients who underwent thoracic CT examination within 30 days before treatment. The exclusion criteria were as follows: (1) patients with adenocarcinoma, cervical EC, or gastroesophageal junction cancer; (2) patients with esophageal multiple primary cancer or other concurrent tumors; (3) patients who received neoadjuvant therapy; (4) CT data not obtained or poor image quality because of incomplete contrast or artifacts; and (5)
missing information, such as age, sex, staging, and location of the tumor. Two databases of patients were used in our study. The nomogram was developed based on 522 EC patients who underwent surgery at the Department of Thoracic Surgery of Henan Cancer Hospital between January 2009 and December 2018. The external validation cohort included consisted of 370 eligible patients identified from the Department of Thoracic Surgery of National Cancer Center/Cancer Hospital from June 2018 to September 2021. This retrospective study involving human participants was reviewed and approved by the Institutional Review Board of the Chinese National Cancer Center, and informed consent was waived due to the retrospective nature of the study.

Surgical procedures

All patients included in this study underwent transthoracic esophagectomy with 2- or 3-field lymphadenectomy. The detailed surgical procedures are described in previous reports (13, 14). During superior mediastinal LN dissection, the upper esophagus was stretched in the right anterior direction by a tape. The left main bronchus and the trachea were rotated using blade forceps in the same direction, which allowed meticulous dissection of LNs deep in the upper mediastinal region. Dissection of the 4L LNs commenced along the upper rim of the left main bronchus. The 4L LNs were dissected carefully with a narrow incision between the left main bronchus and the aortic arch. Below the aortic arch, the recurrent portion of the left recurrent laryngeal nerve was identified. The tissue, including the 4L LNs, was completely removed along the dorsal side of the left pulmonary artery. The station of the lymph node dissected was documented in detail in the surgical procedure record and each patient’s surgical records were searched. The results of 4L lymph node dissection were reconfirmed by the pathological diagnosis report of the lymph nodes. The pathological diagnosis of each lymph node was performed by two pathologists in collaboration.

Patient characteristics, CT-reported 4L LN status and survival

The clinical characteristics included age, sex, degree of differentiation, tumor length, depth of invasion, tumor location, CT-reported 4L LN status, and short and longest axes of the largest 4L LNs. CT images were analyzed by two independent radiologists, using the picture archiving communication system (PACS). The longest axis size of 4L LN was defined as the long axis diameter of the largest 4L LN on the CT scan, and the diameter perpendicular to the long axis of the largest 4L LN was defined as the short axis (15). CT-reported positive LNs were defined as regional LNs with a short-axis diameter greater than 1.0 cm (16, 17). A central low-density mass with an irregular or rim-like enhancement of residual lymphatic tissue was considered as LN necrosis, and conglomerate nodes merging two or more nodes were considered as LN conglomerate (18–20). The overall survival (OS) was measured as the date from diagnosis to the date of death, the time of last contact, or December 2020.

Statistical analysis

The characteristics of patients were all considered as categorical variables and were summarized using percentages. The χ² test or Fisher’s exact test was used to compare patient characteristics between the two groups. Survival curves were generated by a Kaplan–Meier method, and the log-rank test was performed to compare differences. In addition, a propensity score matching (PSM) method was conducted to balance the baseline characteristics between the two groups. In the process of PSM, patients were matched 1:1 according to the nearest propensity score. To calculate propensity scores for each patient, a multiple logistic regression model was performed based on clinically relevant characteristics potentially affecting survival.

Univariable and multivariable logistic regression analyses were applied to identify independent risk factors of 4L LNM. Subsequently, we built the 4L LNM prediction nomogram on the basis of multivariable logistic regression analysis in the training cohort. To test the prediction ability of the nomogram model, the receiver operating characteristic (ROC) curve was performed and the prediction accuracy was evaluated through the area under the curve (AUC) in both the training cohort and the validation cohort. Additionally, calibration curves were plotted to assess the calibration of the nomogram model, accompanied by the Hosmer–Lemeshow test. The discrimination performance of the nomogram model was measured by Harrell’s concordance index (C-index) and subjected to bootstrapping validation with 1,000 resamples to calculate a relatively corrected C-index. Decision curve analysis (DCA) was used in the two cohorts to evaluate the clinical usefulness of the nomogram model. All statistical analyses were performed with R statistical software (version 3.6.0, https://cran.R-project.org). A two-sided p <0.05 was considered statistically significant.

Results

Patient characteristics and survival

A total of 522 patients were included in the training cohort. The clinical and radiological characteristics of all eligible patients are listed in Tables 1, 2. Overall, 41 and 31 patients had 4L LNM in the training and validation cohorts, respectively. The
| Variables                  | Training cohort | Validation cohort |
|----------------------------|-----------------|-------------------|
|                            | 4L− (n = 481)   | 4L+ (n = 41)      | 4L− (n = 339) | 4L+ (n = 31) |
| Age, years                 |                 |                   |              |              |
| <65                        | 257 (90.5%)     | 27 (9.5%)         | 196 (91.2%)  | 19 (8.8%)    |
| ≥65                        | 224 (94.1%)     | 14 (5.9%)         | 143 (92.3%)  | 12 (7.7%)    |
| Sex                        |                 |                   |              |              |
| Male                       | 311 (90.4%)     | 33 (9.6%)         | 257 (90.2%)  | 28 (9.8%)    |
| Female                     | 170 (95.5%)     | 8 (4.5%)          | 82 (96.5%)   | 3 (3.5%)     |
| Smoking index              |                 |                   |              |              |
| ≥400                       | 152 (93.3%)     | 11 (6.7%)         | 90 (87.4%)   | 13 (12.6%)   |
| <400                       | 329 (91.6%)     | 30 (8.4%)         | 249 (93.3%)  | 18 (6.7%)    |
| Tumor length, cm           |                 |                   |              |              |
| ≤3.0                       | 209 (91.3%)     | 20 (8.7%)         | 91 (91.9%)   | 8 (8.1%)     |
| 3.0 < X ≤ 5.0             | 217 (93.5%)     | 15 (6.5%)         | 130 (91.5%)  | 12 (8.5%)    |
| >5.0                       | 55 (90.2%)      | 6 (9.8%)          | 118 (91.5%)  | 11 (8.5%)    |
| Tumor location             |                 |                   |              |              |
| Upper                      | 104 (97.2%)     | 3 (2.8%)          | 38 (90.5%)   | 4 (9.5%)     |
| Middle                     | 302 (91.2%)     | 29 (8.8%)         | 133 (89.3%)  | 16 (10.7%)   |
| Lower                      | 75 (89.3%)      | 9 (10.7%)         | 168 (93.9%)  | 11 (6.1%)    |
| Depth of invasion          |                 |                   |              |              |
| T1/T2                      | 158 (97.5%)     | 4 (2.5%)          | 183 (96.8%)  | 6 (3.2%)     |
| T3/T4a                     | 323 (89.7%)     | 37 (10.3%)        | 156 (86.2%)  | 25 (13.8%)   |
| Tumor differentiation      |                 |                   |              |              |
| Well/moderate              | 301 (95.6%)     | 14 (4.4%)         | 188 (91.3%)  | 18 (8.7%)    |
| Poor                       | 180 (87.0%)     | 27 (13.0%)        | 151 (92.1%)  | 13 (7.9%)    |
| Surgical technique         |                 |                   |              |              |
| MIE                        | 297 (90.3%)     | 32 (9.7%)         | 330 (91.7%)  | 30 (8.3%)    |
| Open                       | 184 (95.3%)     | 9 (4.7%)          | 9 (90.0%)    | 1 (10.0%)    |
| Total number of resected LN|                 |                   |              |              |
| ≤15                        | 92 (94.8%)      | 5 (5.2%)          | 13 (92.9%)   | 1 (7.1%)     |
| 15 < X ≤ 30               | 210 (91.7%)     | 19 (8.3%)         | 102 (91.9%)  | 9 (8.1%)     |
| >30                        | 179 (91.3%)     | 17 (8.7%)         | 224 (91.4%)  | 21 (8.6%)    |
| N stage                    |                 |                   |              |              |
| N0                         | 328 (100.0%)    | 0 (0.0%)          | 166 (100.0%) | 0 (0.0%)     |
| N1                         | 118 (92.2%)     | 10 (7.8%)         | 121 (90.3%)  | 13 (9.7%)    |
| N2                         | 27 (65.9%)      | 14 (34.1%)        | 44 (81.5%)   | 10 (18.5%)   |
| N3                         | 8 (32.0%)       | 17 (68.0%)        | 8 (50.0%)    | 8 (50.0%)    |
| TNM stage                  |                 |                   |              |              |
| I                          | 72 (100.0%)     | 0 (0.0%)          | 40 (100.0%)  | 0 (0.0%)     |
| II                         | 253 (99.6%)     | 1 (0.4%)          | 146 (98.6%)  | 2 (1.4%)     |
| III                        | 147 (87.5%)     | 21 (12.5%)        | 140 (87.0%)  | 21 (13.0%)   |
| IVa                        | 9 (32.1%)       | 19 (67.9%)        | 13 (61.9%)   | 8 (38.1%)    |
| Postoperative complications|                 |                   |              |              |
| Yes                        | 173 (91.5%)     | 16 (8.5%)         | 112 (88.2%)  | 15 (11.8%)   |
| No                         | 308 (92.5%)     | 25 (7.5%)         | 227 (93.4%)  | 16 (6.6%)    |
| Postoperative adjuvant therapy |         |                   |              |              |
| Yes                        | 99 (80.5%)      | 24 (19.5%)        | 178 (86.8%)  | 27 (13.2%)   |
| No                         | 382 (95.7%)     | 17 (4.3%)         | 161 (97.6%)  | 4 (2.4%)     |

LN, lymph node.
4L+ means 4L patients with lymph node metastasis.
4L− means 4L patients without lymph node metastasis.
Table 2 Imaging characteristics of lymph nodes in the training and validation cohorts.

| Variables                        | Training cohort | Validation cohort |
|----------------------------------|-----------------|-------------------|
|                                  | 4L− (n = 481)   | 4L+ (n = 41)      |
|                                  |                 | 4L− (n = 339)    | 4L+ (n = 31)    |
| 2L LN on CT                      |                 |                   |                 |
| Yes                              | 77 (87.5%)      | 11 (12.5%)        | 46 (80.7%)      | 11 (19.3%)      |
| No                               | 404 (93.1%)     | 30 (6.9%)         | 293 (93.6%)     | 20 (6.4%)       |
| Subcarinal LN number on CT       |                 |                   |                 |
| 0                                | 100 (90.1%)     | 11 (9.9%)         | 271 (93.1%)     | 20 (6.9%)       |
| 1–2                              | 217 (91.6%)     | 20 (8.4%)         | 68 (87.2%)      | 10 (12.8%)      |
| ≥3                               | 164 (94.3%)     | 10 (5.7%)         | 0 (0.0%)        | 1 (100.0%)      |
| Paraesophageal LN number on CT   |                 |                   |                 |
| 0                                | 244 (94.6%)     | 14 (5.4%)         | 245 (95.0%)     | 13 (5.0%)       |
| 1–2                              | 136 (91.3%)     | 13 (8.7%)         | 88 (88.0%)      | 12 (12.0%)      |
| ≥3                               | 101 (87.8%)     | 14 (12.2%)        | 6 (50.0%)       | 6 (50.0%)       |
| Longest axis of 4L LN (cm)       |                 |                   |                 |
| <1                               | 381 (96.9%)     | 12 (3.1%)         | 316 (98.4%)     | 5 (1.6%)        |
| 1 ≤ X < 1.5                     | 53 (89.8%)      | 6 (10.2%)         | 21 (67.7%)      | 10 (32.3%)      |
| ≥1.5                             | 47 (67.1%)      | 23 (32.9%)        | 2 (11.1%)       | 16 (88.9%)      |
| Short axis of the largest 4L LN (cm) |             |                   |                 |
| <1                               | 402 (97.1%)     | 12 (2.9%)         | 332 (97.6%)     | 8 (2.4%)        |
| 1 ≤ X < 1.2                     | 50 (84.7%)      | 9 (15.3%)         | 5 (33.3%)       | 10 (66.7%)      |
| ≥1.2                             | 29 (59.2%)      | 20 (40.8%)        | 2 (13.3%)       | 13 (86.7%)      |
| 4L conglomeration                |                 |                   |                 |
| Yes                              | 13 (48.1%)      | 14 (51.9%)        | 5 (33.3%)       | 10 (66.7%)      |
| No                               | 468 (94.5%)     | 27 (5.5%)         | 334 (94.1%)     | 21 (5.9%)       |
| 4L necrosis                      |                 |                   |                 |
| Yes                              | 31 (68.9%)      | 14 (31.1%)        | 5 (25.0%)       | 15 (75.0%)      |
| No                               | 450 (94.3%)     | 27 (5.7%)         | 334 (95.4%)     | 16 (4.6%)       |
| 4L calcification                 |                 |                   |                 |
| Yes                              | 38 (97.4%)      | 1 (2.6%)          | 17 (63.0%)      | 10 (37.0%)      |
| No                               | 443 (91.7%)     | 40 (8.3%)         | 322 (93.9%)     | 21 (6.1%)       |

LN, lymph node; LNM, lymph node metastasis.
4L+ means 4L patients with lymph node metastasis.
4L− means 4L patients without lymph node metastasis.

metastasis rate was 7.9% and 8.4%, respectively (Table 1). As shown in Figure 1A, the 5-year OS rate in patients with 4L LNM was 43.2% and that in patients without 4L LNM was 71.6%. Patients with 4L LNM exhibited a poorer 5-year OS rate than those without (p < 0.001). After PSM, there was no significant difference in patient characteristics between the two groups (p > 0.05; Table 3). Subsequently, survival analysis showed that patients with station 4L LNM had a poorer long-term survival compared with those without (5-year OS rate: 47.2% vs. 76.9%, p = 0.039; Figure 1B).

Development of the nomogram model

Univariate and multivariate logistic regression analyses were performed to identify the independent risk factors associated with 4L LNM (Table 4). Seven variables were confirmed as independent 4L LNM risk factors: sex (odds ratio [OR] = 2.864, 95% confidence interval [CI]: 1.052–7.795, p = 0.039), depth of invasion (OR = 5.464, 95% CI: 1.566–19.062, p = 0.002), tumor differentiation (OR = 2.790, 95% CI: 1.226–6.347, p = 0.016), short axis of the largest 4L LN (OR = 3.096, 95% CI: 1.106–8.668, p = 0.031; OR = 18.675, 95% CI: 7.664–45.507, p < 0.001), 4L conglomeration (OR = 5.534, 95% CI: 1.621–18.885, p = 0.006), and 4L necrosis (OR = 3.701, 95% CI: 1.452–9.432, p = 0.002). The above independent predictors were incorporated to develop a nomogram for predicting the probability of 4L LNM (Figure 2).

Internal and external validations

To test the prediction ability of the nomogram model, internal and external validations were conducted. The AUC of
the nomogram that was constructed on the basis of the training data set was 0.911 (95% CI: 0.869–0.954), demonstrating a good discrimination of 4L LNM (Figure 3A). The calibration curve showed good agreement on the presence of 4L LNM between the risk estimation according to the model and histopathologic results on surgical specimens (Figure 3B). The Hosmer–Lemeshow test demonstrated a non-significant statistic (p = 0.691), which indicated no departure from the perfect fit.

External validation was conducted in an independent cohort. It was then applied to the nomogram and produced an AUC of 0.851 (95% CI: 0.765–0.937), suggesting a good performance of our prediction model (Figure 3C). The calibration curve showed good agreement between the actual and predicted risks of 4L LNM (Figure 3D). The Hosmer–Lemeshow test yielded a p-value of 0.897, indicating a good fit. The DCA for the nomogram model and the models based on CT-reported short or longest axis of the largest 4L LNs is presented in Figure 4. The DCA indicated that, across the majority of the range of risk thresholds, using the nomogram model to predict 4L LNM added the net benefit, and within this range, the highest net benefit emerged with the nomogram model compared with the models of either the longest axis of the largest 4L LNs on CT or the short axis alone. Similar results were obtained in both the training and validation cohorts.

Discussion

Regional lymph node metastasis is a negative prognostic factor in patients with EC (2, 3). 4L LNs are defined as regional LNs according to the UICC/AJCC TNM classification (8th edition) and the Japanese Classification of Esophageal Cancer (10th edition) (6, 7). This study found that the 4L LNM rate was 7.4% in the training group, which was comparable to some previous studies (7, 21). The survival benefit received from 4L lymph node dissection in patients with ESCC has been poorly studied, mainly because of the low metastasis rate of the 4L LN and the limited number of patients receiving the 4L LN dissection (5, 7). This study showed that in the training group, 4L LNM was associated with a poorer prognosis. Currently, there was still controversy about routine prophylactic 4L LN dissection, due to complex adjacent structures and low metastasis rate (7–9). We developed and validated a nomogram model for the individualized prediction of 4L LNM in patients with ESCC. The nomogram model could successfully stratify patients according to their risk of 4L LNM and a 4L lymphadenectomy was performed according to the 4L LNM risk stratification.

Currently, the discrimination of malignant from benign LNs in esophageal cancer with traditional practice based on clinical characteristics remains challenging. In this study, the nomogram model incorporated six clinical and radiological factors based on multivariable logistic regression analysis. Univariate analysis of a previous study found a difference in LNM rates between men and women with esophageal cancer (22). Our study found that male patients showed a higher rate of 4L LNM than female patients. The depth of tumor invasion, as a risk factor for LNM in patients with early ESCC, was supported by some studies (23, 24). Similarly, our results also showed that the depth of invasion was an independent risk factor for 4L LNM. In addition, the grade of differentiation was strongly predictive of LNM according to several reports (24, 25). Tumor differentiation was identified as an independent predictive factor for 4L LNM.
TABLE 3 Clinical characteristics of patients in the training cohorts after PSM.

| Variables             | 4L− (n = 31) | 4L+ (n = 31) | p-value |
|-----------------------|-------------|-------------|---------|
| Age, years            |             |             | 0.796   |
| <65                   | 19 (51.4%)  | 18 (48.6%)  |         |
| ≥65                   | 12 (48.0%)  | 13 (52.0%)  |         |
| Sex                   |             |             | 0.224   |
| Male                  | 22 (45.8%)  | 26 (54.2%)  |         |
| Female                | 9 (64.3%)   | 5 (35.7%)   |         |
| Smoking index         |             |             | 0.576   |
| ≥400                  | 8 (44.4%)   | 10 (55.6%)  |         |
| <400                  | 23 (52.3%)  | 21 (47.7%)  |         |
| Tumor location        |             |             | 0.861   |
| Upper                 | 4 (57.1%)   | 3 (42.9%)   |         |
| Middle                | 21 (51.2%)  | 20 (48.8%)  |         |
| Lower                 | 6 (42.9%)   | 8 (57.1%)   |         |
| Depth of invasion     |             |             | 0.335   |
| T1/T2                 | 8 (25.8%)   | 4 (12.9%)   |         |
| T3/T4a                | 23 (74.2%)  | 27 (87.1%)  |         |
| Tumor differentiation |             |             | 0.127   |
| Well/moderate         | 19 (59.4%)  | 13 (40.6%)  |         |
| Poor                  | 12 (40.0%)  | 18 (60.0%)  |         |
| Surgical technique    |             |             | 0.776   |
| MIE                   | 23 (51.1%)  | 22 (48.9%)  |         |
| Open                  | 8 (47.1%)   | 9 (52.9%)   |         |
| N stage               |             |             | 0.421   |
| N1                    | 15 (60.0%)  | 10 (40.0%)  |         |
| N2                    | 9 (45.0%)   | 11 (55.0%)  |         |
| N3                    | 7 (41.2%)   | 10 (58.8%)  |         |
| TNM stage             |             |             | 0.423   |
| II                    | 1 (50.0%)   | 1 (50.0%)   |         |
| III                   | 23 (56.1%)  | 18 (43.9%)  |         |
| IVa                   | 7 (36.8%)   | 12 (63.2%)  |         |
| Postoperative         |             |             | 0.421   |
| complications         |             |             |         |
| Yes                   | 9 (42.9%)   | 12 (57.1%)  |         |
| No                    | 22 (53.7%)  | 19 (46.3%)  |         |
| Postoperative         |             |             | 0.303   |
| adjuvant therapy      |             |             |         |
| Yes                   | 16 (44.4%)  | 20 (55.6%)  |         |
| No                    | 15 (57.7%)  | 11 (42.3%)  |         |

4L+ means 4L patients with lymph node metastasis.
4L− means 4L patients without lymph node metastasis.

in this study. Therefore, the grade of differentiation was included during the development of the nomogram model.

In clinical practice, preoperative diagnosis of LNM was mainly based on various imaging methods. The detection of LNM on CT images mainly depended on size. In general, intrathoracic and abdominal LNs with a diameter greater than 1.0 cm were considered to be enlarged (15–17). Multivariable analysis in this study showed that the short axis of the largest 4L LNs on imaging was an independent predictive factor for 4L LNM. Similarly, a study reported that the short axis was independently associated with recurrent laryngeal nerve LNM (26). However, unlike the short axis, the longest axis of the largest 4L LNs was not identified as a risk factor in the multivariable analysis, which may be due to confounding caused by other predictive factors, such as the short axis of the largest LNs. Of note, a study suggested that lymph node necrosis was a risk predictor of cervical LNM in patients with head and neck squamous cell carcinoma (18). This was consistent with our results showing that lymph node necrosis and conglomeration were associated with the increased rate of 4L LNM in ESCC. The reason may be that they are the behavioral characteristics of LNM on imaging.
TABLE 4 Univariate and multivariate analyses for 4L lymph node metastasis in the training cohort.

| Variables                                | Univariate analysis | Multivariate analysis |
|------------------------------------------|---------------------|-----------------------|
|                                          | OR (95% CI)         | p-value               | OR (95% CI)         | p-value               |
| Age, years                               | 1.681 (0.860–3.285) | 0.129                 | 2.864 (1.052–7.795) | 0.039                 |
| Sex                                      | 2.255 (1.019–4.992) | 0.045                 |                       |                       |
| Smoking index                            | 0.794 (0.387–1.626) | 0.528                 |                       |                       |
| Tumor length, cm                         | 0.554               |                       |                       |                       |
| ≤3.0                                     | Reference           |                       | Reference            |                       |
| 3.0 < X ≤ 5.0                           | 1.140 (0.437–2.976) | 0.789                 |                       |                       |
| >5.0                                     | 1.578 (0.585–4.255) | 0.367                 |                       |                       |
| Tumor location                           | 0.053               |                       |                       | 0.642                 |
| Upper                                    | Reference           |                       |                       |                       |
| Middle                                   | 0.240 (0.063–0.918) | 0.037                 | 1.847 (0.413–8.273)  | 0.771                 |
| Lower                                    | 0.300 (0.090–1.007) | 0.051                 | 1.747 (0.472–6.466)  | 0.656                 |
| Depth of invasion                        | 4.525 (1.585–12.917) | 0.005               | 5.464 (1.566–19.062) | 0.002                 |
| Tumor differentiation                    | 0.310 (0.185–0.607) | 0.001                 | 2.790 (1.226–6.347)  | 0.016                 |
| Total number of resected LN ≤15          | 0.550               |                       |                       |                       |
| 15 < X ≤ 30                              | 1.747 (0.625–4.887) | 0.287                 |                       |                       |
| >30                                      | 1.050 (0.530–2.080) | 0.889                 |                       |                       |
| 2L LNM on CT                              | 1.924 (0.925–4.002) | 0.080                 | 1.869 (0.760–4.599)  | 0.164                 |
| Subcarinal LNM number on CT 0             | 0.407               |                       |                       |                       |
| 1-2                                      | 0.554 (0.227–1.352) | 0.195                 |                       |                       |
| ≥3                                       | 0.662 (0.302–1.451) | 0.303                 |                       |                       |
| Paraesophageal LNM number on CT 0         | 0.081               |                       |                       | 0.220                 |
| 1-2                                      | 2.416 (1.112–5.250) | 0.026                 | 1.701 (0.667–4.338)  | 0.687                 |
| ≥3                                       | 1.450 (0.653–3.220) | 0.361                 | 2.111 (0.810–5.497)  | 0.151                 |
| Longest axis of 4L LN (cm) <1             | <0.001              |                       |                       | 0.379                 |
| 1 ≤ X ≤ 1.5                              | 15.537 (7.260–33.253) | <0.001         | 1.690 (0.520–5.892)  | 0.194                 |
| ≥1.5                                     | 4.323 (1.621–11.524) | 0.003                 | 0.921 (0.370–1.644)  | 0.337                 |
| Short axis of the largest 4L LN (cm) <1   | <0.001              |                       |                       | 0.001                 |
| 1 ≤ X < 1.5                              | 23.103 (10.290–51.874) | <0.001         | 3.096 (1.106–8.668)  | 0.031                 |
| ≥1.2                                     | 3.831 (1.342–9.519) | 0.004                 | 18.675 (7.664–45.507) | <0.001               |
| 4L conglomeration                        | 18.667 (7.988–43.619) | <0.001         | 5.534 (1.621–18.885) | 0.006                 |
| 4L necrosis                              | 7.527 (3.587–15.792) | <0.001         | 3.701 (1.452–9.432)  | 0.002                 |
| 4L calcification                         | 0.291 (0.039–2.179) | 0.230                 |                       |                       |

OR, odds ratio; 95% CI, 95% confidence interval; LN, lymph node; LNM, lymph node metastasis.
4L+ means 4L patients with lymph node metastasis.
4L- means 4L patients without lymph node metastasis.

Yokota and colleagues (27) indicated that clinical node diagnosis had lower specificity and little predictive value in the preoperative diagnosis of LNM for patients with locally advanced EC. Some studies used the common size criterion of 1.0 cm in CT-reported enlarged nodes, but it showed a low prediction accuracy (13, 14). In addition, the presence of inflammatory and benign enlarged LNs reduced the specificity further. A nomogram was used to help answer a focused clinical question and aid in clinical decision-making. Our study developed the first nomogram model for the prediction of 4L LNM incorporating seven predictive clinical and imaging factors. The DCA indicated that the nomogram model had better diagnostic power for 4L LNM than the traditional LN size criteria, including the models of either the longest axis of the largest 4L LNs on CT images or the short axis alone. Therefore, combined with the results of
validation analyses, we believed that our nomogram model could aid in accurate diagnosis and therapeutic decision-making in 4L lymphadenectomy tailored to individual patients with ESCC. PET/CT, ultrasound-guided bronchoscopy with fine-needle aspiration (EBUS-FNA), and endoscopic esophageal ultrasound-guided fine-needle aspiration (EUS-FNA) had certain advantages in distinguishing malignant and benign lymph nodes, compared with chest CT. Some studies suggested the potential diagnostic roles of PET/CT and EBUS-FNA in detecting LNM (28–30). However, EBUS-FNA and EUS-FNA had high specificity but low negative predictive value and were invasive techniques (31). Moreover, many centers did not routinely perform PET/CT and EBUS-FNA as the initial workup, especially in areas with poor economy or equipment. Due to the limited number of patients receiving PET/CT and EBUS-FNA examinations, we did not include PET/CT and EBUS-FNA assessment in the analysis. In clinical practice and decision-making, for patients who have not received PET/CT and/or EBUS-FNA examination, this model can aid in the prediction of 4L LNM. For patients receiving PET/CT and/or EBUS-FNA, this model can further confirm the results of PET/CT and/or EBUS-FNA examination. Further studies may be needed to reveal whether adding LN characteristics in PET/CT and EBUS-FNA examinations to this nomogram model could improve the predictive efficacy for 4L LNM.

Our study has limitations. Firstly, this is a retrospective study. Excluded patients who did not undergo 4L lymphadenectomy, the interobserver bias among radiologists, and inhomogeneity of surgical techniques still could bias the results. Secondly, this study focused only on the binary classification of patients according to the presence of 4L LNM regardless of the actual quantity. The efficacy of the nomogram model in the prediction of the detailed number of 4L LNM should be verified in further studies. Finally, only CT-reported 4L LN status and short and longest axes of the largest 4L LNs were included in this study. More imaging features, such as CT value, will expand the feature pool, which may result in more valuable factors being identified. Further studies are needed to confirm our findings.

Conclusions

This study developed a nomogram model for the prediction of 4L LNM that was negatively associated with the prognosis of patients with thoracic ESCC. This model that integrated preoperatively the available clinical and radiological risk factors could become an effective tool in predicting 4L LNM.

| Points | 0 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90 | 100 |
|--------|---|----|----|----|----|----|----|----|----|----|-----|
| Sex    | Female | T3/T4a |
| Depth of invasion | T1/T2 |
| Tumour differentiation | Poor |
| Short axis of largest 4L LN | 1sX<1.2cm |
| 4L conglomeration | Yes | No |
| 4L necrosis | Yes | No |

FIGURE 2
Nomogram model for predicting 4L lymph node metastasis (LNM) in patients with thoracic ESCC. The instructions were as follows: locate one patient’s characteristics on the corresponding axis to determine how many points the patient receives, add up the total number of points and locate this point on the total points axis, and draw a vertical line to identify the patient’s probability of 4L LNM.
FIGURE 3
Evaluation of the nomogram model for predicting 4L LNM. Receiver operating characteristic (ROC) curves to discriminate 4L LNM (+) from 4L LNM (−) for the nomogram model in the training cohort (A) and the validation cohort (C). Calibration curves of the nomogram model in the training cohort (B) and the validation cohort (D). Calibration curves depicted the calibration of the nomogram model in terms of agreement between the predicted risk and observed outcomes of 4L LNM.

FIGURE 4
The decision curve analysis (DCA) of the nomogram model for predicting 4L LNM in the training cohort (A) and the validation cohort (B). The red line represented the prediction based on the short axis of the largest 4L LNs alone. The blue line represented the prediction based on the longest axis of the largest 4L LNs alone. The green line represented the nomogram model. Across the majority of the range of risk thresholds, the nomogram model had the highest net benefit compared with the prediction based on either the longest axis or the short axis of the largest 4L LNs alone.
and aid in personalized therapeutic decision-making regarding the need for 4L lymphadenectomy.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

Ethics statement

The Institutional Review Board of Chinese National Cancer Center has reviewed our clinical project, and supported us to conduct the study. This retrospective study was reviewed, and on file, and approved by the Institutional Review Board of Chinese National Cancer Center, and the informed consents were waived, due to the retrospective nature.

Author contributions

Conception and design: All authors. Provision of study materials or patients: LX, JG, H-nX, X-fW, Y-kY, X-kC, and YL. Collection and assembly of data: LX, JG, H-nX, X-fW, Y-kY, PC, R-xZ, X-kC, and YL. Data analysis and interpretation: All authors.

Manuscript writing: All authors. Final approval of manuscript: All authors. Accountable for all aspects of the work: All authors.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660
2. Min BH, Yang JW, Min YW, Baek SY, Kim S, Kim HK, et al. Nomogram for prediction of lymph node metastasis in patients with superficial esophageal squamous cell carcinoma. J Gastrointest Hepatol (2020) 35(6):1009–15. doi: 10.1111/1415
3. Kayani B, Zacharakis E, Ahmed K, Hanna GB. Lymph node metastases and prognosis in oesophageal carcinoma—a systematic review. Eur J Surg Oncol (2011) 37(9):747–53. doi: 10.1016/j.ejso.2011.06.018
4. Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, et al. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw (2019) 17(7):855–83. doi: 10.6004/jnccn.2019.0033
5. Harada K, Hwang H, Wang X, Abdelhakeem A, Iwatsuki M, Blum Murphy MA, et al. Frequency and implications of paratracheal lymph node metastases in resectable esophageal or gastroesophageal junction adenocarcinoma. Ann Surg (2021) 273(4):751–7. doi: 10.1097/SLA.0000000000003383
6. Amin MB, Edge S, Greene F, Byrd D, Brookland R, Washington M, et al. AJCC cancer staging manual. 8th ed. New York: Springer (2017).
7. Liu J, Kang M, Chen S, Deng F, Han Z, Lin J. Feasibility and strategy for left thoracoscopic lymph node dissection in thoracolaparoscopic esophageal cancer surgery. Thorac Cancer (2016) 7(2):199–206. doi: 10.1111/1759-7714.12312
8. Wang YN, Yao S, Wang CL, Li MS, Sun LN, Yan QN, et al. Clinical significance of 4L lymph node dissection in left lung cancer. J Clin Oncol (2018) 36(29):2935–42. doi: 10.1200/JCO.2018.78.7101
9. Flamen P, Lerat A, Van Cutsen E, De Weyer W, Peeters M, Stroobants S, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol (2000) 18(18):3202–10. doi: 10.1200/JCO.2000.18.3202
10. van Westreenen HL, Westerterp M, Bossuyt PM, Pusim J, Soofo GW, van Lanschot JJ, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol (2004) 22(18):3805–12. doi: 10.1200/JCO.2004.01.083
11. Sgourakis G, Gockel I, Lyros O, Hansen T, Mäderlenberger P, Lang H. Detection of lymph node metastases in esophageal cancer. Expert Rev Anticancer Ther (2011) 11(4):601–12. doi: 10.1586/era.10.150
12. Schroeder W, Baldus SE, Mönig SF, Beckertis TK, Dienes HP, Hölscher AH, et al. Lymph node staging of esophageal squamous cell carcinoma in patients with and without neoadjuvant radiochemotherapy: histomorphologic analysis. World J Surg (2002) 26(5):584–7. doi: 10.1007/s00268-001-0275-1
13. Sun HB, Li Y, Liu XB, Zhang RX, Wang ZF, Lerut T, et al. Early oral feeding following McKeown minimally invasive esophagectomy: an open-label, randomized, controlled, noninferiority trial. Ann Surg (2018) 267(3):435–42. doi: 10.1097/SLA.0000000000002304
14. Sun HB, Li Y, Liu XB, Zhang RX, Wang ZF, Zheng Y, et al. Embedded three-layer esophagogastric anastomosis reduces morbidity and improves short-term outcomes after esophagectomy for cancer. Ann Thorac Surg (2016) 101(3):1131–8. doi: 10.1016/j.athoracsur.2015.09.094
15. Wang ZL, Zhuo ZG, Chen Y, Li XT, Sun YS. Support vector machines model of computed tomography for assessing lymph node metastasis in esophageal cancer with neoadjuvant chemotheraphy. J Comput Assist Tomogr (2017) 41(3):455–60. doi: 10.1097/RCT.0000000000000555
16. Hong SJ, Kim TJ, Nam KR, Lee IS, Yang HC, Cho S, et al. New TNM staging system for esophageal cancer: what chest radiologists need to know. Radiographics (2014) 34(6):1722–40. doi: 10.1148/rg.346130709
17. Zhao B, Zhu HT, Li XT, Shi YJ, Cao K, Sun YS, et al. Predicting lymph node metastasis using computed tomography radiomics analysis in patients with resectable esophageal squamous cell carcinoma. J Comput Assist Tomogr (2021) 45(2):323–9. doi: 10.1097/RCT.0000000000001125

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
18. Chung MS, Choi YJ, Kim SO, Lee YS, Hong JY, Lee JH, et al. A scoring system for prediction of cervical lymph node metastasis in patients with head and neck squamous cell carcinoma. AJNR Am J Neuroradiol (2019) 40(6):1049–54. doi: 10.3174/ajnr.A6066

19. van den Brekel MW, Stel HV, Castelijns JA, Nauta JJ, van der Waal I, Valk I, et al. Cervical lymph node metastasis: assessment of radiologic criteria. Radiology (1990) 177(2):379–84. doi: 10.1148/radiology.177.2.2217772

20. Shafii A, Bagheri M, Farhadi F, Apole AB, Bassou NM, Folio LR, et al. CT evaluation of lymph nodes that merge or split during the course of a clinical trial: Limitations of RECIST 1.1. Radiol Imaging Cancer (2021) 3(3):e200090. doi: 10.1148/rycan.2021200090

21. Udagawa H, Ueno M, Shinohara H, Haruta S, Kaida S, Nakagawa M, et al. The importance of grouping of lymph node stations and rationale of three-field lymphoadenectomy for thoracic esophageal cancer. J Surg Oncol (2012) 106(6):742–7. doi: 10.1002/jso.23122

22. Gockel I, Domeyer M, Spourakis GG, Schimanski CC, Moehler M, Kirkpatrick CJ, et al. Prediction model of lymph node metastasis in superficial esophageal adenocarcinoma and squamous cell cancer including D2-40 immunostaining. J Surg Oncol (2009) 100(3):191–8. doi: 10.1002/jso.21336

23. Zheng H, Tang H, Wang H, Fang Y, Shen Y, Feng M, et al. Nomogram to predict lymph node metastasis in patients with early esophageal squamous cell carcinoma. Br J Surg (2018) 105(11):1464–70. doi: 10.1002/bjs.10882

24. Wu J, Chen QX, Shen DJ, Zhao Q, A prediction model for lymph node metastasis in T1 esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg (2018) 155(4):1902–8. doi: 10.1016/j.jtcvs.2017.11.005

25. Rice TW, Ishwaran H, Hofstetter WL, Schipper PH, Kesler KA, Law S, et al. Esophageal cancer: Associations with (pN+) lymph node metastases. Ann Surg (2017) 265(1):122–9. doi: 10.1097/SLA.0000000000001594

26. Zhang G, Li Y, Wang Q, Zheng H, Yuan L, Gao Z, et al. Development of a prediction model for the risk of recurrent laryngeal nerve lymph node metastasis in thoracolaparoscopic esophagectomy with cervical anastomosis. Ann Transl Med (2021) 9(12):990. doi: 10.21037/atm-21-2374

27. Yokota T, Igaki H, Kato K, Tsuobos Y, Mizusawa J, Katayama H, et al. Accuracy of preoperative diagnosis of lymph node metastasis for thoracic esophageal cancer patients from JCOG9907 trial. Int J Clin Oncol (2016) 21(2):283–8. doi: 10.1007/s10147-015-0899-z

28. Moon SH, Kim HS, Huyun SH, Choi YS, Zo JI, Shim YM, et al. Prediction of occult lymph node metastasis by metabolic parameters in patients with clinically N0 esophageal squamous cell carcinoma. J Nucl Med (2014) 55(5):743–8. doi: 10.2967/jnumed.113.130716

29. Xu M, Wang L, Ouyang M, Lin J, Wang L, Zheng X, et al. Prediction of lymph node metastasis by PET/CT metabolic parameters in patients with esophageal squamous cell carcinoma. Nucl Med Commun (2019) 40(9):933–9. doi: 10.1097/MNM.0000000000001050

30. Verhoeven RLJ, Trisolini R, Leoncini F, Candoli P, Bezzi M, Messi A, et al. Predictive value of endobronchial ultrasound strain elastography in mediastinal lymph node staging: The e-predict multicenter study results. Respiration (2020) 99(6):484–92. doi: 10.1159/000507592

31. De Leyn P, Lardinois D, Van Schil PE, Rami-Porta R, Paslick R, Zschieschi M, et al. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg (2007) 32(1):1–8. doi: 10.1016/j.ejcts.2007.01.075